Nurse on Trial for Fraudulent Use of Patient Details for Prescriptions
A County Down aesthetics nurse, Nichola Hawes, is on trial for allegedly using patients' details to prescribe medications like Ozempic and Botox without consent, following an investigation launched by the Medicines Regulatory Group in November 2022 after a potential breach in regulations was reporte...
Nurse on Trial for Fraudulent Use of Patient Details for Prescriptions
A County Down aesthetics nurse, Nichola Hawes, is on trial for allegedly using patients' details to prescribe medications like Ozempic and Botox without consent, following an investigation launched by the Medicines Regulatory Group in November 2022 after a potential breach in regulations was reporte...
Progress
32% Bias Score
Medicare Part D Drug Cost Cap Set at $2,000 Annually Starting in 2025
The Inflation Reduction Act institutes a $2,000 annual out-of-pocket cap on Medicare Part D prescription drug costs starting in 2025, benefiting over 3 million enrollees without low-income subsidies, with this number projected to reach over 4 million by 2029; insurers will cover 60% of costs in the ...
Medicare Part D Drug Cost Cap Set at $2,000 Annually Starting in 2025
The Inflation Reduction Act institutes a $2,000 annual out-of-pocket cap on Medicare Part D prescription drug costs starting in 2025, benefiting over 3 million enrollees without low-income subsidies, with this number projected to reach over 4 million by 2029; insurers will cover 60% of costs in the ...
Progress
48% Bias Score
Medicare Caps Annual Out-of-Pocket Prescription Drug Costs at $2,000
Starting January 1, 2025, Medicare will cap annual out-of-pocket prescription drug costs at $2,000 for its 65 million enrollees, a move expected to significantly aid cancer patients and other older adults facing high medication expenses, particularly those on fixed incomes.
Medicare Caps Annual Out-of-Pocket Prescription Drug Costs at $2,000
Starting January 1, 2025, Medicare will cap annual out-of-pocket prescription drug costs at $2,000 for its 65 million enrollees, a move expected to significantly aid cancer patients and other older adults facing high medication expenses, particularly those on fixed incomes.
Progress
36% Bias Score
France's Most Prescribed Drugs
Analysis of the most prescribed drugs in France, highlighting Doliprane's dominance and the high cost of innovative treatments.
France's Most Prescribed Drugs
Analysis of the most prescribed drugs in France, highlighting Doliprane's dominance and the high cost of innovative treatments.
Progress
0% Bias Score
Trump Reverses Biden Healthcare Policies
President Trump issued an executive order on Monday to reverse several Biden administration healthcare policies, including measures to reduce prescription drug costs for Medicare and Medicaid beneficiaries and strengthen the Affordable Care Act; experts predict minimal immediate impact on consumer c...
Trump Reverses Biden Healthcare Policies
President Trump issued an executive order on Monday to reverse several Biden administration healthcare policies, including measures to reduce prescription drug costs for Medicare and Medicaid beneficiaries and strengthen the Affordable Care Act; experts predict minimal immediate impact on consumer c...
Progress
40% Bias Score
Medicare Drug Cost Cap Set at $2,000 Annually Starting in 2025
The Inflation Reduction Act of 2022 caps out-of-pocket Medicare Part D prescription drug costs at $2,000 annually starting in 2025, benefiting over 3 million enrollees initially, rising to over 4 million by 2029, with roughly 40% seeing annual savings of at least $1,000; insurers received roughly $5...
Medicare Drug Cost Cap Set at $2,000 Annually Starting in 2025
The Inflation Reduction Act of 2022 caps out-of-pocket Medicare Part D prescription drug costs at $2,000 annually starting in 2025, benefiting over 3 million enrollees initially, rising to over 4 million by 2029, with roughly 40% seeing annual savings of at least $1,000; insurers received roughly $5...
Progress
36% Bias Score
Spain to Allow Pharmacists to Dispense Repeat Prescriptions for Chronic Conditions
Spain is considering a new law allowing pharmacists to dispense repeat prescriptions for chronic conditions like migraines after an initial doctor's visit, aiming to improve patient access to necessary medications; however, concerns about patient safety and potential overmedication remain.
Spain to Allow Pharmacists to Dispense Repeat Prescriptions for Chronic Conditions
Spain is considering a new law allowing pharmacists to dispense repeat prescriptions for chronic conditions like migraines after an initial doctor's visit, aiming to improve patient access to necessary medications; however, concerns about patient safety and potential overmedication remain.
Progress
20% Bias Score